|
注册号: Registration number: |
ChiCTR2400088883 |
|
最近更新日期: Date of Last Refreshed on: |
2024-08-28 17:36:14 |
|
注册时间: Date of Registration: |
2024-08-28 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
布比卡因脂质体注射液用于痔切除术术后急性疼痛 |
|
Public title: |
Bupivacaine liposomal injection for acute pain after hemorrhoidectomy |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
布比卡因脂质体注射液用于痔切除术术后急性疼痛的有效性和安全性:一项全国多中心、双向性、队列研究 |
|
Scientific title: |
Efficacy and safety of bupivacaine liposomal injection for acute pain after hemorrhoidectomy: a national multicenter, ambispective, cohort study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
王小峰 |
研究负责人: |
章阳 |
|
Applicant: |
Xiaofeng Wang |
Study leader: |
Yang Zhang |
|
申请注册联系人电话: Applicant telephone: |
+86 139 1599 4007 |
研究负责人电话:
Study leader's |
+86 131 8283 5012 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
wxf_1982@163.com |
研究负责人电子邮件: Study leader's E-mail: |
21670235@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江苏省南京市大明路157号 |
研究负责人通讯地址: |
江苏省南京市大明路157号 |
|
Applicant address: |
157 Daming Road, Nanjing City, Jiangsu Province |
Study leader's address: |
157 Daming Road, Nanjing City, Jiangsu Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
南京市中医院 |
||
|
Applicant's institution: |
Nanjing Traditional Chinese Medicine Hospital |
||
|
研究负责人所在单位: |
南京市中医院 |
||
|
Affiliation of the Leader: |
Nanjing Traditional Chinese Medicine Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
KY2024007 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南京市中医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee Of Nanjing Traditional Chinese Medicine Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-03-01 00:00:00 | ||
|
伦理委员会联系人: |
刘铮 |
||
|
Contact Name of the ethic committee: |
Zheng Liu |
||
|
伦理委员会联系地址: |
江苏省南京市大明路157号 |
||
|
Contact Address of the ethic committee: |
157 Daming Road, Nanjing City, Jiangsu Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 25 5227 6505 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
南京市中医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Nanjing Traditional Chinese Medicine Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏省南京市大明路157号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
157 Daming Road, Nanjing City, Jiangsu Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
研究经费自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
The research was self-funded |
||||||||||||||||||||||
|
研究疾病: |
痔切除术 |
||||||||||||||||||||||
|
Target disease: |
Haemorrhoidectomy |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
1.主要研究目的 在真实世界中观察和描述布比卡因脂质体用于痔切除术术后中重度急性疼痛的有效性。 2.次要研究目的 在真实世界中观察和描述布比卡因脂质体用于痔切除术术后中重度急性疼痛的安全性和耐受性。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. Main objectives of the study To observe and describe the effectiveness of liposomal bupivacaine for moderate to severe acute pain after hemorrhoidectomy in the real world. 2. Secondary objectives of the study To observe and describe the safety and tolerability of liposomal bupivacaine for moderate to severe acute pain after hemorrhoidectomy in the real world. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
前瞻队列: 1. 合并精神系统疾病及认知功能障碍的患者; 2. 合并痛觉过敏等感觉障碍、或存在影响术后疼痛评估的其他躯体疼痛的患者; 3. 半年内有心肌梗死或不稳定型心绞痛病史,或严重心律失常病史(如有Ⅱ度及Ⅱ度以上房室传导阻滞); 4. 合并糖尿病周围神经病变的患者; 5. 肝功能异常:天门冬氨酸氨基转移酶(AST)或/和丙氨酸氨基转移酶(ALT)和/或总胆红素(TBIL)≥1.5×ULN; 6. 已知对布比卡因或其他酰胺类局麻药过敏者; 7. 妊娠、哺乳期女性患者; 8. 研究者认为具有任何不适合参加此试验的其他因素的患者。 回顾队列: 1. 同时合并非手术部位的其他身体部位疼痛的患者,或存在慢性疼痛的患者; 2. 关键研究相关数据信息缺失的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Prospective cohort: 1. Patients with comorbid mental disorders and cognitive impairment; 2. Patients with sensory disorders such as hyperalgesia, or other bodily pain affecting postoperative pain assessment; 3. The history of myocardial infarction, unstable angina pectoris, or severe arrhythmia (such as atrioventricular block of degree Ⅱ or above) within 6 months; 4. Patients with diabetic peripheral neuropathy; 5. Abnormal liver function: aspartate aminotransferase (AST) or/and alanine aminotransferase (ALT) and/or total bilirubin (TBIL) ≥1.5×ULN; 6. Known to be allergic to bupivacaine or other amide local anesthetics; 7. Pregnant and lactating women; 8. Patients with any other factor considered by the investigator to be ineligible for the trial. Retrospective cohort: 1. Patients with concurrent pain in other parts of the body other than the surgical site, or patients with chronic pain; 2. Patients with missing data information related to key studies. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-02-01 00:00:00至 To 2025-12-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-07-02 00:00:00 至 To 2025-10-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
计划在研究论文公开发表后6个月内(预计2017年6月30日之前)公开原始数据,采用临床试验公共管理平台 ResMan (www.medresman.org)共享原始数据供公众浏览。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The original data will be available for public viewing within six months of publication of the study paper (expected to be no later than June 30, 2017) using ResMan (www.medresman.org), a public clinical trial management platform. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
研究通过电子采集和管理系统(Electronic Data Capture, EDC)采集数据。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data were collected through an Electronic Data Capture and management system (EDC). |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |